ghp June 2015

26 | ghp June 2015 innovation Stem Cells Could Expand Window for Treating Stroke Each year nearly 800,000 people in the United States suffer a stroke. Most of these – nearly 87 percent – are ischemic strokes caused by blood flow to the brain being blocked usually by a clot. Without oxygen the brain cells begin to die and death or permanent disability can result. Currently the only FDA-approved treatment for strokes is tissue plasminogen activator (tPA) a drug that works by dissolving the clot and restoring blood flow. Unfortunately to be effective tPA must be administered within about five hours of the stroke and many victims don’t get to the hospital in time to receive it. Another downside is the drug can exacerbate leakage of the blood-brain barrier (which separates the brain from the circulatory system) and increase the chance for abnormal bleeding. This has left medical re- searchers searching for something that offers a wider treatment timeframe without negative side effects. Among the more promising of these is stem cell trans- plantation using neural stem cells derived from pluri- potent stem cells (iPSC-NSCs) reprogrammed from the patient’s own cells. These cells appear to possess multiple therapeutic benefits including replacing the damaged brain cells and fighting inflammation. In the study researchers from Tulane University (New Orleans LA) conducted studies testing the effective- ness of iPSCs during the early stages of an ischemic stroke. Lead investigator Jean-Pyo Lee Ph.D. of Tulane’s Centre for Stem Cell Research and Regenera- tive Medicine and Department of Neurology explained “A good deal of stroke injury results from reperfusion – when the blood flow is restored after the stroke. If left unchecked reperfusion can cause an irreversible second opening of the blood-brain barrier within 24 to 72 hours after the first stroke occurs.” A recent study in STEM CELLS Translational Medicine could open the door to a new therapy to po- tentially expand the current window of time for treating patients after they have experienced a stroke (five times beyond that of a clot-busting drug) and significantly improves their chance of recovery. “It is this second episode that contributes significantly to cell death” she said. “The goal of our study was to find a way to limit early-stage blood-brain barrier inju- ries an outcome that would protect against the second phase of stroke damage.” Using mice as their test model 24 hours after stroke the researchers transplanted iPSC-NSCs into the animals’ ipsilesional hippocampus a natural niche of NSCs in the brain. In another 24 hours (48 hours after stroke) the stem cells had migrated to the stroke lesion and quickly improved the animals’ neurological function. Recovery of behavioural function persisted throughout the month-long monitoring period the team reported. “The rapid therapeutic activity is not due to cell replacement but to a bystander effect that elicits re- duced inflammation and blood-brain barrier damage” Dr. Lee said. “The results have clinical implications by indicating a much extended treatment window (24 hours as opposed to the maximum five hours for tPA). Plus there is the potential for a synergistic effect by combining transplanted hiPSC-NSCs with tPA to reduce a stroke’s adverse effects.” “This is an interesting study that points to the potential of induced pluripotent stem cells to improve neurolog- ical function after a stroke,” said Anthony Atala M.D. Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regener- ative Medicine. “Results in mice showed significant improvement in sensorimotor balance and motor function two to eight days after injury which was maintained during the one-month study period.”